Lv5
1230 积分 2021-08-18 加入
Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC
11天前
已完结
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
12天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
2个月前
已完结
311eP Exploration of the mechanism of anlotinib in reversing PD-1 immunotherapy resistance: Insights from single-cell sequencing
4个月前
已完结
Successful treatment of severe lung cancer caused by third-generation EGFR-TKI resistance due to EGFR genotype conversion with afatinib plus anlotinib
4个月前
已完结
Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
6个月前
已完结
Dealing with KRAS G12C inhibition in non-small cell lung cancer (NSCLC) – biology, clinical results and future directions
6个月前
已完结
Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis
7个月前
已完结
HER2 testing: evolution and update for a companion diagnostic assay
7个月前
已完结
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer
8个月前
已关闭
皖公网安备34019202002308
